logo

Investors

Investors

EpimAb is supported by an international consortium of investors and has raised $25 million in a Series A financing round to advance the Company’s pipeline of novel bispecific antibodies. The investors include Oriza Seed Capital, Decheng Capital, 3E Bioventure Capital and the Trend Investment Group.